PT - JOURNAL ARTICLE AU - Ronan Doorley AU - Alex Berke AU - Ariel Noyman AU - Luis Alonso AU - Josep Ribó AU - Vanesa Arroyo AU - Marc Pons AU - Kent Larson TI - Mobility and COVID-19 in Andorra: Country-scale analysis of high-resolution mobility patterns and infection spread AID - 10.1101/2021.02.18.21251977 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.18.21251977 4099 - http://medrxiv.org/content/early/2021/02/24/2021.02.18.21251977.short 4100 - http://medrxiv.org/content/early/2021/02/24/2021.02.18.21251977.full AB - In the absence of effective vaccines, non-pharmaceutical interventions, such as mobility restrictions, were globally adopted as critically important strategies for curbing the spread of COVID-19. However, such interventions come with immense social and economic costs and the relative effectiveness of different mobility restrictions are not well understood. This study analyzed uniquely comprehensive datasets for the entirety of a small country, consisting of serology data, telecoms data, and COVID-19 case reports, in order to examine the relationship between mobility and transmission of COVID-19.Andorra is a small European country where tourism is a large part of the economy. Stringent mobility restrictions were put in place in Spring 2020. Additionally, 91% of the population participated in a voluntary COVID-19 serology testing programme and those data were made available for this study. Furthermore, high resolution telecoms data for the entire population were available for analysis of mobility and proximity patterns. A set of mobility metrics were developed to indicate levels of crowding, stay-at-home rates, trip-making and contact with tourists. Mobility metrics were compared to infection rates across communities and transmission rate over time.Several of these metrics were highly correlated with transmission rate, with a lead time of approximately 18 days, with some metrics more highly correlated than others. There was a stronger correlation for measures of crowding and inter-community trip-making, and a weaker correlation for total trips (including intra-community trips) and stay-at-homes rates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Andorra Innovation Hub provided financial support to the City Science Group at MIT Media LabAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The serological screening was approved by the relevant Andorran regulatory agencies and the local Research Ethics Committee. Participation in the screening was entirely voluntary. The Institutional Review Board of the Servei Andorra Atencio Sanitaria (SAAS) approved the study (register number 0720). The study was supported and approved by the Andorran government.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe telecoms data and the serology screening data are not publicly available.